P.5.b.001 Cochrane review of valproate preparations for agitation in dementia

Narayana, Usha; Clifton, Andrew; Luxenberg, Jay S.; Curran, Stephen

doi:10.1016/s0924-977x(15)30816-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other agents that have shown efficacy in this population are anticonvulsants with carbamazepine having RCT level evidence 200,201 . Valproic acid showed some favorable results in open label trials but these findings were not replicated in RCTs where there was a clear lack of benefit and a high rate of adverse events, and thus it is not recommended for use in this population 202 . In addition, when used to treat people with dementia, retrospective evidence suggests that valproic acid has an increased mortality rate, comparable to some antipsychotics and possibly higher than the atypical antipsychotic quetiapine 203 .…”

Section: Treatment Of Agitation and Impulsivity In Pre‐dementia Syndromesmentioning

confidence: 99%

Agitation and impulsivity in mid and late life as possible risk markers for incident dementia

Bateman

Gill

et al. 2020

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

To identify knowledge gaps regarding new‐onset agitation and impulsivity prior to onset of cognitive impairment or dementia the International Society to Advance Alzheimer's Research and Treatment Neuropsychiatric Syndromes (NPS) Professional Interest Area conducted a scoping review. Extending a series of reviews exploring the pre‐dementia risk syndrome Mild Behavioral Impairment (MBI), we focused on late‐onset agitation and impulsivity (the MBI impulse dyscontrol domain) and risk of incident cognitive decline and dementia. This scoping review of agitation and impulsivity pre‐dementia syndromes summarizes the current biomedical literature in terms of epidemiology, diagnosis and measurement, neurobiology, neuroimaging, biomarkers, course and prognosis, treatment, and ongoing clinical trials. Validations for pre‐dementia scales such as the MBI Checklist, and incorporation into longitudinal and intervention trials, are needed to better understand impulse dyscontrol as a risk factor for mild cognitive impairment and dementia.

show abstract

Section: Treatment Of Agitation and Impulsivity In Pre‐dementia Syndromesmentioning

confidence: 99%